Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Amicus Therapeutics (FOLD) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Amicus Therapeutics (FOLD) over the last 17 years, with Q3 2025 value amounting to 20.27%.

  • Amicus Therapeutics' EBITDA Margin rose 49700.0% to 20.27% in Q3 2025 from the same period last year, while for Sep 2025 it was 5.48%, marking a year-over-year increase of 44200.0%. This contributed to the annual value of 5.66% for FY2024, which is 237900.0% up from last year.
  • As of Q3 2025, Amicus Therapeutics' EBITDA Margin stood at 20.27%, which was up 49700.0% from 6.12% recorded in Q2 2025.
  • Amicus Therapeutics' EBITDA Margin's 5-year high stood at 20.27% during Q3 2025, with a 5-year trough of 95.71% in Q1 2022.
  • Its 5-year average for EBITDA Margin is 31.27%, with a median of 25.11% in 2024.
  • Per our database at Business Quant, Amicus Therapeutics' EBITDA Margin plummeted by -249200bps in 2022 and then skyrocketed by 551200bps in 2023.
  • Amicus Therapeutics' EBITDA Margin (Quarter) stood at 87.82% in 2021, then skyrocketed by 45bps to 48.05% in 2022, then surged by 93bps to 3.21% in 2023, then surged by 433bps to 10.67% in 2024, then surged by 90bps to 20.27% in 2025.
  • Its last three reported values are 20.27% in Q3 2025, 6.12% for Q2 2025, and 6.35% during Q1 2025.